RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

Figure 1: The RUNX1/AP-1 axis operates differently in different types of AML. Cytokine receptors are indicated in different colours with their ligand shown as coloured round shapes on the cell surface ...

The development of resistance and relapse during the blast phase of chronic myeloid leukemia poses a challenge in the management of this pathology, with half of the cases accounting for FLT3 pathway ...

The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...